Tumor News and Research

RSS

Exelixis files new drug application for a proprietary novel anticancer compound

Exelixis, Inc. has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for XL999, a proprietary novel anticancer compound.

29 Jun 2004

A gene involved in the adhesion of cells is less active in breast tumors with a poor prognosis than those that are less aggressive

Physicians may be able to make early decisions on the best treatment for breast cancer, thanks to research published in Breast Cancer Research today.

28 Jun 2004

50,000 people in the U.S. with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery

50,000 people or 10% of the 500,000 people in the U.S with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery for coverage of life saving drugs.

26 Jun 2004

First-ever microfluidic BioMEMS device to study the mechanisms of cell migration and deformation

Cancer cells have the ability to invade blood vessels and find their way into the bloodstream. Once there, these infected cells can easily travel to other parts of the body and attack healthy organs.

25 Jun 2004

Ingredient of human breast milk may be a new treatment for warts

New Swedish research suggests that HAMLET or "Human-lactalbumin made lethal to tumor cells" an ingredient of human breast milk may be a new treatment for warts.

24 Jun 2004

Microchip to track genetic signature of cancer and normal tissue

MicroRNAs (miRNAs), tiny pieces of genetic material that can serve as stop signs for gene expression and protein synthesis, are thought to be important in the development of cancer.

23 Jun 2004

Partial breast radiation procedure may benefit cancer patients

Some women with breast cancer who prefer breast conserving surgery consisting of lumpectomy and radiation may choose a procedure that delivers radiation to the malignant tumor and not to the entire breast

23 Jun 2004

Prostate and kidney cancer can be detected in urine

Bladder cancer is the fourth most common male cancer in the Western world. There will be more than 44,6000 new cases of bladder cancer diagnosed in U.S. men this year and more than 15,600 new cases diagnosed in women As many as 25 percent of these cancers are diagnosed after the disease is advanced, leading to a poor prognosis.

23 Jun 2004

Discovery of a gene-expression signature common to distinct types of cancer

Researchers at the University of Michigan, Johns Hopkins and the Institute of Bioinformatics in India have discovered a gene-expression "signature" common to distinct types of cancer

23 Jun 2004

Cognitive decline can occur before chemotherapy treatment

In a series of studies in breast cancer patients, researchers at The University of Texas M. D. Anderson Cancer Center have confirmed the presence of “chemobrain” after chemotherapy treatment – but they also discovered that a significant portion of patients have cognitive declines even before chemotherapy.

21 Jun 2004

Early patient response to Forteo in postmenopausal women with osteoporosis

Changes in markers of bone remodeling after one month of treatment with FORTEO® (teriparatide [rDNA origin] injection) may provide important early evidence of treatment response, according to new data presented today at the 86th Annual Meeting of The Endocrine Society (ENDO).

17 Jun 2004

Xenobiotic gets patent approval for toxin detection

XDS consultant (and former XDS laboratory director) Michael Chu and President George Clark combined their research skills to develop a rapid and relatively inexpensive methodology to quantify TEQs (Toxic Equivalence -- measures of toxicity adopted by the World Health Organization) for individual toxic chemical groups.

17 Jun 2004

Ultrasound technology to treat cancer

Ultrasound scans might be most familiar for getting a peek at a developing fetus, but the technology could also be used to treat cancer. A partnership between UC Davis, Siemens Medical Systems and ImaRx Inc., funded by a National Cancer Institute grant, will study ways to deliver drugs to tumors using focused ultrasound.

17 Jun 2004

Potential new strategy for blocking tumor growth

Targeting a master molecule that helps cancer cells survive when blood oxygen levels are low may offer a potentially powerful strategy for blocking tumor growth, say researchers at The University of Texas M. D. Anderson Cancer Center.

16 Jun 2004

Results from study of Rituxan in rheumatoid arthritis show promise

Genentech, Inc., Biogen Idec and Roche have announced that the New England Journal of Medicine published the results of a Phase IIa study showing that two doses of Rituxan® (Rituximab), administered two weeks apart, improved symptoms in patients with moderate-to-severe rheumatoid arthritis (RA) for up to 48 weeks when combined with methotrexate (MTX), compared to MTX alone.

16 Jun 2004

New target to stop breast cancer growth

Two proteins that normally help cells move from place to place and are made in large quantities in breast cancer cells work together to promote the survival and spread of breast cancer, according to a new study by scientists at The University of Texas M. D. Anderson Cancer Center.

15 Jun 2004

New whole body positron emission tomography (PET) imaging allows scientists to watch as immune system respond to tumors or infection

Compared to the snapshot views of the immune system from tumor biopsies or blood assays, this whole body imaging allows scientists to track how the immune response changes, and the tumor or infection responds, throughout the different phases of immune response and over long periods of time.

15 Jun 2004

Cancer drug gefitinib (Iressa) may be able to restore tamoxifen's anticancer activity

A new study has found a possible mechanism for tamoxifen resistance in breast cancer and provides evidence that another cancer drug--gefitinib (Iressa)--may be able to restore tamoxifen's anticancer activity.

15 Jun 2004

Investigational drug Abraxane is active and well tolerated in women with metastatic breast cancer

Investigational drug Abraxane™ (albumin nanoparticle paclitaxel), administered weekly without steroid premedication, is active and well tolerated in women with metastatic breast cancer whose disease had progressed while they were treated with paclitaxel (Taxol®) and/or docetaxel (Taxotere®).

15 Jun 2004

African-American women less likely to survive breast cancer than white women

A new study led by investigators at Fred Hutchinson Cancer Research Center may help explain why African-American women with breast cancer are more likely to be diagnosed with advanced disease and are less likely to survive the disease than white women.

15 Jun 2004